Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Completed
National Cancer Institute (NCI)
Phase 1
1999-07-01
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine.
This would allow the cancer to be detected and treated by radioactive iodine.
PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function
in treating patients who have persistent or metastatic thyroid cancer.
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Completed
Lucille P. Markey Cancer Center at University of Kentucky
Phase 1
1999-07-01
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine.
This would allow the cancer to be detected and treated by radioactive iodine.
PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function
in treating patients who have persistent or metastatic thyroid cancer.
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine
(Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease
during cardiopulmonary bypass surgery.
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
Unknown status
National Cancer Institute (NCI)
Phase 2
2004-10-01
RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive
iodine.
PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients
with locoregionally extensive or metastatic thyroid cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.